Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

NCT01328886 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: Omalizumab

Sponsor

Novartis Pharmaceuticals